NCI-2022-02385: Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia (clinicaltrials.gov) - Oct 2, 2026 - P2 | N=30 | Recruiting | Sponsor: Jonathan Brammer | Trial completion date: Jul 2026 ➔ Jul 2027 | Trial primary completion date: Jul 2026 ➔ Jul 2027
Trial completion date • Trial primary completion date • Hematological Malignancies • Leukemia • Neutropenia • Oncology • T-Cell Large Granular Lymphocyte Leukemia • B3GAT1 • CD4 • CD8
|